Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion
- PMID: 11809934
- DOI: 10.1093/protein/14.12.1035
Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion
Abstract
Anti-CD3 immunotoxins exhibit considerable promise for the induction of transplantation tolerance in pre-clinical large animal models. Recently an anti-human anti-CD3epsilon single-chain immunotoxin based on truncated diphtheria toxin has been described that can be expressed in CHO cells that have been mutated to diphtheria toxin resistance. After the two toxin glycosylation sites were removed, the bioactivity of the expressed immunotoxin was nearly equal to that of the chemically conjugated immunotoxin. This immunotoxin, A-dmDT390-sFv, contains diphtheria toxin to residue 390 at the N-terminus followed by VL and VH domains of antibody UCHT1 linked by a (G(4)S)(3) spacer (sFv). Surprisingly, we now report that this immunotoxin is severely compromised in its binding affinity toward CD3(+) cells as compared with the intact parental UCHT1 antibody, the UCHT1 Fab fragment or the engineered UCHT1 sFv domain alone. Binding was increased 7-fold by adding an additional identical sFv domain to the immunotoxin generating a divalent construct, A-dmDT390-bisFv (G(4)S). In vitro potency increased 10-fold over the chemically conjugated immunotoxin, UCHT1-CRM9 and the monovalent A-dmDT390-sFv. The in vivo potency of the genetically engineered immunotoxins was assayed in the transgenic heterozygote mouse, tgepsilon 600, in which the T-cells express human CD3epsilon as well as murine CD3epsilon. T-cell depletion in the spleen and lymph node observed with the divalent construct was increased 9- and 34-fold, respectively, compared with the monovalent construct. The additional sFv domain appears partially to compensate for steric hindrance of immunotoxin binding due to the large N-terminal toxin domain.
Similar articles
-
Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.Mol Immunol. 2001 Sep;38(5):397-408. doi: 10.1016/s0161-5890(01)00070-0. Mol Immunol. 2001. PMID: 11684296
-
Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1).Cancer Immunol Immunother. 2008 Aug;57(8):1225-39. doi: 10.1007/s00262-008-0457-x. Epub 2008 Feb 7. Cancer Immunol Immunother. 2008. PMID: 18256829 Free PMC article.
-
Genetic construction and characterization of an anti-monkey CD3 single-chain immunotoxin with a truncated diphtheria toxin.Bioconjug Chem. 1997 Sep-Oct;8(5):695-701. doi: 10.1021/bc9701398. Bioconjug Chem. 1997. PMID: 9327133
-
Treatment with immunotoxin.Philos Trans R Soc Lond B Biol Sci. 2001 May 29;356(1409):681-9. doi: 10.1098/rstb.2001.0839. Philos Trans R Soc Lond B Biol Sci. 2001. PMID: 11375071 Free PMC article. Review.
-
Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.Curr Drug Targets. 2009 Feb;10(2):104-9. doi: 10.2174/138945009787354539. Curr Drug Targets. 2009. PMID: 19199905 Review.
Cited by
-
Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Haematologica. 2015 Jun;100(6):794-800. doi: 10.3324/haematol.2015.123711. Epub 2015 Mar 20. Haematologica. 2015. PMID: 25795722 Free PMC article. Clinical Trial.
-
Hosts for Hostile Protein Production: The Challenge of Recombinant Immunotoxin Expression.Biomedicines. 2019 May 17;7(2):38. doi: 10.3390/biomedicines7020038. Biomedicines. 2019. PMID: 31108917 Free PMC article. Review.
-
Construction, expression and characterization of human interferon alpha2b-(G4S)n-thymosin alpha1 fusion proteins in Pichia pastoris.World J Gastroenterol. 2005 May 7;11(17):2597-602. doi: 10.3748/wjg.v11.i17.2597. World J Gastroenterol. 2005. PMID: 15849818 Free PMC article.
-
An anti-PSMA bivalent immunotoxin exhibits specificity and efficacy for prostate cancer imaging and therapy.Adv Healthc Mater. 2013 May;2(5):736-44. doi: 10.1002/adhm.201200254. Epub 2012 Nov 22. Adv Healthc Mater. 2013. PMID: 23184611 Free PMC article.
-
CD3e-immunotoxin spares CD62Llo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3ehi T cells.Front Immunol. 2022 Oct 26;13:1011190. doi: 10.3389/fimmu.2022.1011190. eCollection 2022. Front Immunol. 2022. PMID: 36389741 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources